CHANDLER THIBODAUX: Open Payments
NPI 1205974045 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,934 in 130 payments from 19 companies in 2025. Trend: 2023 $2,847 · 2024 $2,665 · 2025 $2,934
Food & beverage: $2,934
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 14 | $604 |
| Regeneron Healthcare Solutions, Inc. | 16 | $466 |
| UCB, Inc. | 22 | $304 |
| Galderma Laboratories, L.P. | 10 | $231 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 9 | $222 |
| Arcutis Biotherapeutics, Inc. | 15 | $219 |
| Novartis Pharmaceuticals Corporation | 8 | $194 |
| LEO Pharma Inc. | 7 | $145 |
| Amgen Inc. | 5 | $114 |
| ABBVIE INC. | 5 | $96 |
Products named: DUPIXENT, Bimzelx, NEMLUVIO, Zoryve, ILUMYA, ANZUPGO, OTEZLA, COSENTYX.
Industry payments across TX — which companies pay providers there.
